Diabetes Home > Thiazolidinediones
Although thiazolidinedione products may be effective for controlling blood sugar levels, these drugs have been linked to potentially serious heart complications. Rosiglitazone and pioglitazone are the two drugs in the thiazolidinedione class, and both have received black box warnings from the FDA. These warnings state that these products can increase the risk for heart failure and may cause or exacerbate heart failure symptoms.
What Are Thiazolidinediones?Thiazolidinediones are a group of prescription medications approved for the treatment of type 2 diabetes. These medications work by improving the body's natural response to insulin. Troglitazone (Rezulin®) was the first drug in this class approved by the U.S. Food and Drug Administration (FDA) in 1997, but was withdrawn from the market in 2000 due to the drug's potential to cause liver damage.
- Rosiglitazone and glimepiride (Avandaryl®)
- Rosiglitazone and metformin (Avandamet®)
- Pioglitazone and glimepiride (Duetact®)
- Pioglitazone and metformin (Actoplus Met®)
- Pioglitazone and metformin XR (Actoplus Met® XR).
- Those who are already being successfully treated on the medication
- Those whose blood sugar levels cannot be controlled using any other medication
- Those who do not wish to take pioglitazone-containing medicines after consulting with their healthcare provider.